Araris Biotech AG develops antibody-drug conjugate (ADC) linker technology for cancer therapies. The company, a spin-off from the Paul Scherrer Institute and ETH Zurich, focuses on creating a proprietary platform that enables payload attachment to antibodies without re-engineering.

Araris

Araris Biotech AG is pioneering a novel linker technology for antibody-drug conjugates (ADCs.) Our linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering.

Innosuisse

Venture Kick

Redalpine

Schroder Adveq

VI Partners

btov Partners

4BIO Capital

Kinled Holding

Pureos Bioventures

Wille AG

Wille Finance

Follicular Lymphoma Innovation

Schroders Capital

Samsung Ventures

Araris Biotech AG

In case you missed it, we were recognized as one of the top seven innovative companies revolutionizing #AntibodyDrugConjugate (ADC) drug development in @Clarivate for Life Sciences & Healthcare’s Companies to Watch: Antibody Drug Conjugates report. For more information, download the full report here: https://bit.ly/4dlirZ6

Reminder that our Chief Scientific Officer, @Philipp Spycher, Ph.D., is speaking at the 2nd annual ADC Linker & Conjugation Summit in Boston, MA on Thursday, August 22nd at 12pm ET. He will be sharing insights about our development of highly stable multi-payload #AntibodyDrugConjugates (ADCs). For more information and to register, visit here: https://bit.ly/3qxC5hT

Excited to share that our CSO Philipp Spycher, Ph.D., was recently featured on a Drug Target Review webinar! Tune in to hear his insights on current advancements in immunotherapies, including #AntibodyDrugConjugates, for cancer treatment. Listen now: https://lnkd.in/ggyq7k6S

ADC technologies face challenges, including poor ADC exposure and solubility with limited chemical flexibility of the linker. Our #ADCTechnology generates homogenous, highly soluble, and stable ADCs with an antibody-like exposure profile at flexible drug load. In just one step, this approach has the potential to make a clinically meaningful difference for patients. Learn more: https://bit.ly/3WpB2fM

Our Co-Founder and Chief Scientific Officer, Philipp Spycher, Ph.D., will be speaking about the development of novel dual-payload antibody-drug conjugates (ADCs) at the 2nd annual ADC Linker & Conjugation Summit on Thursday, August 22nd at 12pm ET. For more information and to register, visit here: https://lnkd.in/eQWiftp7

Don’t forget to sign up for an insightful webinar where experts, including our own Co-founder & CSO, Philipp Spycher, Ph.D., will discuss immunotherapy advancements that are transforming cancer treatment. The panelists will explore the current landscape of immunotherapy research, including insights into recent developments and obstacles encountered within the field. To register for free and learn more, please visit here: https://lnkd.in/ggyq7k6S

We’re thrilled to be included as one of the top seven innovative companies revolutionizing antibody-drug conjugate (ADC) drug development in this report from Clarivate for Life Sciences & Healthcare. For more information, download the full report here: https://lnkd.in/eCSaAWtu

Our Co-Founder and Chief Scientific Officer, Philipp Spycher, Ph.D., will be a panelist on Drug Target Review's “Immunotherapy Advancements: Transforming Cancer Treatment” webinar on July 29th at 10am EDT. Join the webinar to hear more about Araris’ antibody-drug conjugates as a revolutionary approach in cancer treatment. To register for free and learn more, please visit here: https://lnkd.in/ggyq7k6S

In case you missed it, we presented data at the @American Association for Cancer Research (AACR) Annual Meeting 2024 on two novel dual TOP1i ADCs targeting HER2 and NaPi2b that showed high stability and high anti-tumor activity in mouse models. Read more here: https://bit.ly/3Kp6tBq

We’re pleased to announce we’ve appointed Ulf Grawunder, Ph.D. to our scientific advisory board. His wealth of knowledge and experience in the #ADC space will be instrumental as we continue to innovate our proprietary ADC technology and develop our pipeline of next-generation ADC therapies. Read more: https://bit.ly/3xgdUaT

Hostpoint

Engineering

Philipp Probst

Business Management

Romain BERTRAND

Information Technology

Isabella Attinger-Toller

Philipp Spycher

Ramona Stark

Arnd Kaltofen

Michael Sidler

Damir Jacob Illich

Co-founder and CEO

Co-founder and VP Translational Research

Filippo Mulinacci

Chief Business Officer

Dragan Grabulovski

Co-founder

Zurich Companies With Less Than $10M in Revenue

Zurich Companies With Less Than $1B in Revenue

Switzerland Companies With Fewer Than 100 Employees (Top 10K)

Zurich Health Care Companies

Araris Biotech AG (Araris) is a biotechnology start-up company. Their aim is to deliver a breakthrough technology platform that enables the development of next-generation ADC-based safe and potent drugs for various diseases and ailments.They are committed to produce high quality ADCs that do not require any engineering (antibody and/or cell-line) for site-specific conjugation instead the antibodies can directly be taken 'off-the-shelf'. The site-specifically modified ADCs can thus be produced rapidly within a few days and quality control and analysis can be performed quickly with high confidence. Their ADC technology is backed by two patents.

Grant - Araris Biotech

Venture Round - Araris Biotech

Series A - Araris Biotech

Seed Round - Araris Biotech

Pre Seed Round - Araris Biotech

Zürich

Zurich

Switzerland

Europe

Araris Biotech

Araris Biotech expands its IP portfolio

Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs)

Araris Biotech AG’s Post

Araris Biotech AG on LinkedIn: Our Co-Founder and Chief Scientific Officer, Philipp Spycher, Ph.D., will…

Araris Biotech AG Appoints Dr. Ulf Grawunder to Scientific Advisory Board

Araris Biotech AG on LinkedIn: #adc #aacr24

Top antibody-drug conjugate (ADC) companies leading the industry

The top 5 ADC startups favoured by venture capital investors

Samsung Ventures Invests In Araris Biotech

Russian Federation

Germany

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 4, 2024 5:58 AM	bf98f4aa
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 4, 2024 10:35 AM	a8558a95
company summary	general
signals	general
crunchbase trigger	general	Nov 12, 2024 12:52 PM	4128509e
crunchbase profile	general	Nov 12, 2024 2:10 PM	a06219d3
li profile	general	Sep 4, 2024 5:58 AM	886ca1b1
translate crunchbase fundingrounds	general	Nov 12, 2024 2:25 PM	83516d6d
peers	general	Sep 4, 2024 5:58 AM	b385e31b
news basic	general	Sep 4, 2024 5:58 AM	417f3063
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:ARARISBIOTECH

Araris